ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Audentes to build gene therapy plant in North Carolina

by Ryan Cross
February 22, 2020 | APPEARED IN VOLUME 98, ISSUE 8

 

Audentes Therapeutics is the latest drug company with plans to build a gene therapy manufacturing plant in North Carolina. Audentes, which was recently bought by Astellas Pharma for $3 billion, says it will spend $109 million to build a 12,500 m2 facility in Sanford. Bluebird Bio, Novartis, and Pfizer also have gene therapy sites in North Carolina. Audentes says the plant will create more than 200 new jobs. The firm has only one gene therapy in clinical trials.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment